What Facts Should You Know About EQRx (EQRX)?

By Ken Smith • Thursday, October 05 16:31 • Permanent Link

Mid-cap health care company EQRx has moved 0.9% this evening, reaching $2.22 per share. In contrast, the average analyst target price for the stock is $2.1.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company is based in the United States.

What to Consider if You Are Thinking of Buying EQRx:

EQRx has moved -57.0% over the last year.
EQRX has a forward P/E ratio of -3.3 based on its EPS guidance of -0.67.
Over the last 2 years, earnings per share (EPS) have been growing at a compounded average rate of -60.4%.
Its Price to Book (P/B) ratio is 0.86

EQRx Has None

Date Reported	Cash Flow from Operations ($ k)	Capital expenditures ($ k)	Free Cash Flow ($ k)	YoY Growth (%)
2023-02-23	-287,268	-1,133	-286,135	-56.59
2022-02-10	-183,180	-448	-182,732

None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.